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Objective: Asthma is one of the most common medical conditions complicating pregnancy.
Despite the presence of published guidelines outlining the care of the pregnant patient with
asthma, disparities in the treatment of acute asthma exacerbations in the emergency depart-
ment related to pregnancy status are known to exist. We sought to determine if pregnancy
status affected the treatment of women presenting to a tertiary emergency department for
care of acute asthma exacerbations.
Methods: We retrospectively compared the emergency department treatment of acute asthma
exacerbations in 123 pregnant women to 123 non-pregnant controls. Asthma exacerbations
were classified by severity according to pre-determined criteria.
Results: In the emergency department (ED), pregnant women were significantly less likely to
be treated with systemic corticosteroids than non-pregnant controls (50.8% versus 72.4%,
p Z 0.001). Similarly, 41% of pregnant women received prescriptions for prednisone at the
time of discharge from the ED compared to 69.2% of non-pregnant women (p < 0.001).
Conclusions: In this population of asthmatics presenting to a tertiary emergency department
with acute asthma exacerbations, pregnant women were less likely to receive appropriate
therapy with systemic corticosteroids.
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There is disparity in asthma care resulting in higher rates of
morbidity for minority groups, lower socioeconomic classes
and urban populations.1 Women are disproportionately
affected, as asthma rates are higher for women than for
men and women are more likely to live at or below poverty
level.2 Pregnancy may further increase vulnerability for
high risk groups.3,4
Asthma is one of the most common serious medical
conditions to complicate pregnancy, with approximately
8% of pregnancies affected.5 Asthma exacerbations
during pregnancy are common, with 12.6e51.9% of
women likely to experience an asthma exacerbation
during pregnancy depending on the underlying severity of
their disease.6 However, the effects of pregnancy on
overall asthma control are often quite variable with
reports of 23% of women experiencing improvement in
asthma control and 30% noting worsening during
pregnancy, with pre-pregnancy asthma severity seeming
to be most predictive of asthma course during pregn-
ancy provided that appropriate asthma therapy is
continued.6,7Importance
Recent studies have highlighted under-utilization of
controller medications in pregnant women with asthma
during pregnancy but have not been designed to explore
the reasons underlying these potential treatment dispar-
ities.8,9 In 1999 Cydulka and colleagues found that pregnant
women who presented to an emergency department (ED)
for treatment for an acute asthma exacerbation were less
likely to receive appropriate treatment with systemic
corticosteroids than non-pregnant women, highlighting
suboptimal care of the pregnant asthmatic during an acute
exacerbation.4 These findings are surprising considering the
National Asthma Education and Prevention Program
(NAEPP) published the first guidelines outlining asthma care
during pregnancy in 1993, providing evidenced based prin-
ciples for maintenance therapy and treatment of exacer-
bations which are nearly equivalent to those of the
non-pregnant patient.10 Interestingly, the literature is
relatively void of similar studies since 1999, and it is not
known if practice patterns have changed particularly since
the NAEPP published updated guidelines for managing
asthma in pregnancy in 2004.5Goals of this investigation
The purpose of this study was to compare the clinical
presentation and treatment of acute asthma in the emer-
gency department between pregnant and non-pregnant
women and to assess the adequacy of therapy for acute
exacerbations when compared to currently published
guidelines.Methods
Study design and selection of participants
We retrospectively compared the emergency department
treatment of acute asthma exacerbations in pregnant
women to non-pregnant controls. Potential subjects were
identified through the assistance of an electronic database
which identified women who presented to the emergency
department at a single tertiary care center with the diag-
noses of asthma and pregnancy between January 1996 and
September 2009. Non-pregnant women presenting to the
emergency department with acute asthma exacerbations
were selected as controls and were matched according to
age, race, and year of visit. The institutional review board
at the participating institution deemed the study exempt
from formal review.
Inclusion criteria included age 18e45 and clinical history
consistent with an acute asthma exacerbation as deter-
mined by the treating clinician. Repeat visits by individual
subjects were excluded. 809 potential pregnant women
with asthma exacerbations were identified, with 686
records excluded as a result of repeat visits for individual
subjects or ED encounters for non-asthma related
complaints. The medical records of 123 pregnant women
and 123 controls were reviewed.
Data collection
The medical records of all subjects were retrospectively
reviewed. Data was collected on a standardized data
collection form to assess patient demographic character-
istics, current asthma medications, details of current
asthma exacerbation, ED management and disposition, and
perinatal outcomes (when available). Return visits to the
ED for persistent or worsening asthma symptoms were
recorded if they occurred during the two weeks following
the observed period. Asthma exacerbations were classified
according to severity based on the following criteria (Table
1): 1). “Mild” exacerbations: dyspnea with activity,
peak expiratory flow (PEF)  70% predicted, or sympt-
oms relieved by  1 short-acting bronchodilator in the ED
2). “Moderate” exacerbations: dyspnea interferes with
usual activity, PEF 40e69% predicted, or symptoms relieved
with 2e3 short-acting bronchodilators in the ED 3).
“Severe” exacerbations: dyspnea with conversation or at
rest, PEF < 40% predicted, or symptoms requiring > 3 short-
acting bronchodilators in the ED 4). “Life threatening”
exacerbations: distress or too dyspneic to speak, PEF < 25%
predicted, and symptoms requiring > 3 short-acting bron-
chodilators in the ED.
Primary data analysis
We compared demographic and clinical characteristics
between pregnant and non-pregnant subjects using the
two-sample t-test for continuous variables and Fisher’s
exact test for categorical variables. Continuous variables
were assessed for normality and equal variance across the
two groups in order to run the two-sample t-test. Cate-
gorical variables are presented as counts and percents
Table 1 Classification of severity of asthma exacerbation at presentation to the emergency department.
Symptoms & signs Initial peak expiratory
flow rate (PEF)
Short-acting bronchodilator
treatments required for
symptom relief in the ED
Mild Dyspnea with activity PEF  70% predicted 1
Moderate Dyspnea interferes with usual activity PEF 40e69% predicted 2e3
Severe Conversational dyspnea or at rest PEF < 40% predicted >3
Life threatening Distress, too dyspneic to speak PEF < 25% predicted >3
EDZ emergency department; PEFZ peak expiratory flow. Adapted from National Asthma Education and Prevention Program (NAEPP).
Expert Panel Report 3: guidelines for the diagnosis and management of asthma: full report 2007.
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standard deviations. All analyses were run using Stata 10.1,
Stata Corporation, College Station, TX.Results
The study included 123 pregnant women and 123 non-
pregnant controls. Demographic data and baseline asthma
medications are summarized in Table 2. The subjects were
matched by age, race, and year of visit. Pregnant women
weremore likely to have health insurance coverage provided
by Medicaid, and were less likely to be taking oral leuko-
triene modifiers at the time of presentation. Otherwise, the
groups were similar.Table 2 Demographic characteristics of participants.
Non-pregnan
n 123
Age, mean (sd) 24.7 (5.6)
Race, %
White 24.4
Black 74.0
Other 1.6
Insurance, %
Private 32.5
Medicaid 39.8
None 27.6
Current smoker, %
No 56.1
Yes 25.2
Unknown 18.7
Hospital at presentation
Main University, % 62.6
University Affiliate, % 37.4
Current Medication Use, %
Short-acting b-agonist 68.9
Inhaled anti-cholinergic 2.5
Long-acting b-agonist (LABA) 5.7
Inhaled corticosteroids (ICS) 15.6
Combination ICS/LABA 13.1
Oral leukotriene modifier 13.9
Theophylline 3.3
Prednisone 4.9
sd Z standard deviation; LABA Z long-acting b-agonist; ICS Z inhaleAsthma related symptoms on presentation for pregnant
and non-pregnant women are shown in Table 3. The groups
were similar in terms of duration of preceding symptoms,
self-reported antecedent viral respiratory illnesses, and
reported non-adherence to use of inhaled corticosteroids
prior to ED presentation (10.8% in controls vs. 16.1% in
pregnant women, pZ 0.167). In those women who reported
non-adherence to use of inhaled corticosteroids, all non-
pregnant controls (n Z 4) reported running out of their
medications while 40% (nZ 2) of pregnant women reported
running out of their medication and 60% (n Z 3) reported
discontinuing themedications specifically due to pregnancy.
Use of the classification for severity of exacerbation did not
reveal any statistically significant differences by pregnancy
status; a similar proportion of non-pregnant versus pregnantt Pregnant p-value
123
24.9 (5.4) e
25.2 e
73.2 e
1.6 e
22.2 <0.001
67.5
10.3
54.5 0.939
27.6
17.9
56.6 0.364
43.4
73.0 0.573
1.7 0.999
4.1 0.769
12.4 0.580
11.6 0.846
4.1 0.012
1.6 0.446
2.5 0.500
d corticosteroids.
Table 3 Clinical characteristics of participants.
Non-pregnant Pregnant p-value
n Z 123 n Z 123
Duration of symptoms, %
 3 h 8.6 4.2 0.397
4e23 h 35.6 31.1
1e7 days 51.3 53.8
> 7 days 14.5 10.8
Exacerbation severity, %
Mild 18.7 31.1 0.090
Moderate 61.0 52.1
Severe/life threatening 20.3 16.8
Respiratory rate, mean 21.3 20.9 0.473
Oxygen saturation [SpO2%], mean 96.1 97.6 0.148
Associated viral symptoms, % 56.9 56.2 0.999
Stopped inhaled corticosteroids preceding ED visit, % 10.8 16.1 0.167
ED visit for asthma in preceding six months, % 10.6 16.3 0.261
ED Z emergency department.
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31.1% respectively), moderate exacerbations (61.0% versus
52.1%) and severe/life threatening exacerbations (20.3%
versus 16.8%); overall pZ 0.090. Peak expiratory flow rates
and arterial blood gas values were recorded when available,
but due to the extremely small sample size, no analysis was
performed (data not shown).
Pregnant and non-pregnant women received comparable
numbers of aerosolized short-acting bronchodilators while in
the ED as one would expect for similar levels of severity, yet
pregnant women were significantly less likely to be treated
with systemic corticosteroids in the ED (50.8% versus 72.4%,
pZ 0.001) (Table 4). It does not appear that the decreased
use of systemic steroids in the pregnant patients was related
to treatment biases related to trimester of pregnancy. Forty-
five percent of patients presenting during the first trimester
(n Z 40) received systemic corticosteroids compared toTable 4 Emergency department treatment and disposition.
Bronchodilator given in ED, % Albuterol
Albuterol/ipratroprium
Number of nebulized short-
acting bronchodilators
received in ED, mean (sd)
Systemic corticosteroids given
in ED, %
Corticosteroids given at
discharge from ED, %
None
Prednisone
Inhaled corticosteroids
Both
Disposition, % Discharge
Admission or observation
labor & delivery
Representation to ED within
two weeks, %
ED Z emergency department; sd Z standard deviation.56.1% (nZ 57) of those presenting in the second trimester,
and 55.6% (nZ 18) of those presenting in the third trimester
(pZ 0.549). Similar disparities in prescribing patterns were
noted in patients discharged from the ED, where pregnant
women were significantly less likely to be prescribed corti-
costeroids compared to non-pregnant controls. Forty-one
percent of pregnant women received prescriptions for
prednisone at the time of discharge from the ED compared to
69.2% of non-pregnant women, while inhaled corticosteroids
(ICS) were prescribed infrequently in both groups (3.7%
versus 2.5% respectively for ICS alone and 3.7% versus 7.5%
for ICS in combination with prednisone, overall p < 0.001).
Severity of asthma exacerbation did seem to influence
the use of systemic corticosteroids (Table 5). During
treatment in the ED, pregnant women with moderate
exacerbations were significantly less likely to receive
systemic corticosteroids (56.5% versus 77.3% respectively,Non-pregnant
(n Z 123)
Pregnant
(n Z 123)
p-value
41.7 49.1 0.290
58.3 50.9
2.6 (1.4) 2.3 (1.5) 0.097
72.4 50.8 0.001
20.8 51.4 <0.001
69.2 41.3
2.5 3.7
7.5 3.7
95.1 87.7 0.066
in 4.9 12.3
2.5 9.7 0.026
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(18.9% versus 34.8%, p Z 0.223) or severe/life threatening
exacerbations (95% versus 88%, p Z 0.617). At the time of
discharge from the ED, pregnant women with both mild and
moderate exacerbations were significantly less likely to
receive prescriptions for prednisone (13.5% versus 47.8%,
pZ 0.007, and 50.9% versus 75.7%, pZ 0.011 respectively)
but there was no difference noted for severe/life threat-
ening exacerbations (78.6% versus 72.7%, p Z 0.628).
Year of treatment did not influence the decision to use
systemic corticosteroids in either patient group, with
similar results noted when subjects were divided into two
groups: 1996e2004 and 2005e2009 to account for the
possible influence of the updated asthma in pregnancy
guidelines (data not shown).5
Pregnant women exhibited a trend toward more frequent
hospitalizations for their asthma exacerbations with 12.3%
being admitted or observed for at least 24 h versus only 4.9%
of non-pregnant women (p 0.066). More notable is the
observation that pregnant women were nearly four times
more likely than non-pregnant women to represent to this
same institution’s ED for recurrent or persistent asthma
symptoms within two weeks (9.7% versus 2.5%, p Z 0.026).
However, the small sample size precludes detailed analysis.
In the small subset of women in whom pregnancy outcome
data was available, there were no significant associations
with use of systemic corticosteroids (Table 6).Discussion
In this retrospective case-control analysis of acute asthma
exacerbations, we found that pregnant and non-pregnant
women presented to the ED with similar clinical charac-
teristics and asthma severity. However, pregnant women
were under-treated with systemic corticosteroids both in
the ED and at the time of discharge when compared to their
non-pregnant counterparts. Moreover, pregnant women
were nearly four times more likely than non-pregnant
women to return to the same ED within two weeks for
recurrent or on-going asthma symptoms.Table 5 Corticosteroids administered in the emergency departm
Asthma severity Mild
Pregnant No Yes p-value
Systemic
corticosteroids
given in ED, %
34.8
(n Z 23)
18.9
(n Z 37)
0.223
Corticosteroids
given at
discharge from
ED, %
n Z 23 n Z 37
None 47.8 81.1 0.007
Prednisone 47.8 13.5
Inhaled
corticosteroids
0 2.7
Both 4.4 2.7
ED Z emergency department.Our findings are similar to those noted by Cydulka et al4
in a prospective study of pregnant women presenting to the
ED with acute asthma exacerbations, where they noted
that pregnant women were significantly less likely to be
treated with systemic corticosteroids in the ED or at
discharge when compared to non-pregnant women (44%
versus 66%, p Z 0.002 and 38% versus 64%, p Z 0.002
respectively). These authors also noted that pregnant
women were three times more likely to report on-going
asthma symptoms at two week follow-up.
Treatment differences according to pregnancy status
may be based on concerns about potential harmful effects
of medications on the fetus or lack of familiarity with
current national guidelines. While the risks and benefits of
any medication used during pregnancy must always be
considered, little debate exists regarding the safety of
inhaled corticosteroids (ICS) during pregnancy.5 Investiga-
tors have shown that ICS improve asthma control during
pregnancy11,12 and reduce hospitalizations.13 However, the
use of these controller medications often decreases during
pregnancy8,14,15 leading to an increase in ED visits.15
Although our study did not specifically address changes in
medication adherence related to pregnancy, we do note
with some concern that only 24% of the pregnant women in
our study reported use of ICS at the time of their ED visit
despite the evident severity of their disease (Table 2).
The most notable difference between the treatment of
pregnant and non-pregnant women in this study involved
the use of systemic corticosteroids. Currently available
guidelines and expert statements5,16 recommend the use of
systemic corticosteroids for acute asthma exacerbations
during pregnancy similar to the management in non-
pregnant patients, as uncontrolled maternal asthma may
increase the risk of adverse perinatal outcomes.17e23
However, women with well-controlled asthma in preg-
nancy generally have good pregnancy outcomes.12,24,25
The use of oral corticosteroids in pregnant women is
associated with some risk. Oral corticosteroid use during the
first trimester of pregnancy has been associated with a 3-fold
increased risk for cleft lip with or without cleft palate in
women taking it for many reasons.26 Schatz and colleaguesent by severity of asthma exacerbation and pregnancy status.
Moderate Severe/life threatening
No Yes p-value No Yes p-value
77.3
(n Z 75)
56.5
(n Z 62)
0.011 88
(n Z 25)
95
(n Z 20)
0.617
n Z 75 n Z 59 n Z 22 n Z 14
17.3 40.7 0.011 4.6 14.3 0.628
75.7 50.9 72.7 78.6
2.8 5.1 12.4 0.0
5.3 3.4 18.2 7.1
Table 6 Pregnancy related outcomes.
Corticosteroids administered in ED p-value
No Yes
Occurrence of
spontaneous abortion,
% (n)
8.1 (3/37) 2.6 (1/38) 0.358
Preterm labor, % (n) 24.2 (8/33) 11.4 (4/35) 0.211
APGAR 1 min < 7, % (n) 3.0 (1/33) 19.4 (7/36) 0.057
APGAR 5 min < 7, % (n) 3.0 (1/33) 2.9 (1/35) 0.999
Trimester of pregnancy
at time of ED
presentation, %
First 40.0 (22/55) 30.0 (18/60) 0.549
Second 45.5 (25/55) 53.3 (32/60)
Third 14.5 (8/55) 16.7 (10/60)
Gestational age in weeks
at time of delivery,
mean [sd] (n)
37.8 [2.1](27) 36.6 [5.9](29) 0.329
Birth weight in grams,
mean [sd] (n)
2947 [605](32) 3.192 [631](32) 0.119
APGAR Z Apgar score; ED Z emergency department; sd Z standard deviation; n Z number.
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labor,28 and low birth weights28 in the offspring of asthmatic
women who received systemic corticosteroids even after
adjusting for potential confounding variables. Bracken and
colleagues found similar results in a prospective cohort of
women.29 Perlow and coworkers described an increased
incidence of diabetes mellitus, preterm labor and delivery,
low birth weight infants, and premature rupture of
membranes in 31 steroid-dependant pregnant asthmatics.30
Unfortunately, it remains difficult to clearly separate the
potential effects of the medications from the potential
effects of poorly controlled maternal asthma in many cases.
There was a trend towards more frequent need for
hospitalization in the pregnant women in our study, but this
did not reach statistical significance, perhaps due to the
small sample size. Despite this, the pregnant women were
nearly four times more likely to return to the same ED with
persistent or recurrent asthma symptoms within two
weeks. This is similar to the findings noted by Cydulka and
colleagues,4 where the pregnant women were three times
more likely to report on-going asthma symptoms at two
week follow-up. Although lack of corticosteroid treatment
in the ED or at discharge may have contributed to these
findings, the small sample size prohibited detailed analysis.
Additional contributing factors such as the impact of
asthma-specific quality of life must be considered. Schatz
and coworkers found that asthma-specific quality of life
predicts subsequent exacerbations in pregnancy.31Limitations
This study has several potential limitations. First, the retro-
spective study design limited our ability to more objectively
characterize the subjects at the time of presentation. We
attempted to account for this by including the exacerbation
severity classification descriptions noted above. Similarly,
wewere unable to evaluate on-going asthma symptoms after
discharge from the emergency department, andwere limitedby the fact that some subjects with persistent or recurrent
asthma exacerbations may have chosen to seek further care
at other facilities. Accordingly, wemay have underestimated
the possible effects of not treating pregnant women with
asthma exacerbations with systemic corticosteroids in this
study. Our statistical power is limited by the relatively small
number of pregnant women (n Z 123) presenting to the ED
for acute asthma exacerbations. This may reflect the policy
that all pregnant patients after a certain point in pregnancy
be triaged to “labor and delivery” for any medical evalua-
tion, or it may reflect an inability of the computerized
database to identify all potential subjects. Since our patients
were enrolled from a single academic ED and its community
affiliated hospital, they may not be representative of the
medical community as a whole. However, because emer-
gency physicians in academic centers are more likely to have
been exposed to national asthma guidelines than those
practicing in other settings,32 our findings may actually be an
underestimation rather than an overestimation. Finally, the
potential influence of the pregnant patients’ own desire (or
lack thereof) to receive treatment with systemic cortico-
steroids could not be assessed in this retrospective study, and
could have potentially accounted for some of the treatment
differences we observed.
Regardless of these limitations, we have identified an
area of significant potential concern. Despite two nationally
published guidelines specifically addressing the care of the
pregnant patient with asthma,5,10 there does not appear to
have been a significant impact on the clinical care of these
patients with an acute exacerbation in the emergency
department setting when comparing our data to those pub-
lished by Cydulka and colleagues over a decade ago.4
In summary,we found that in this population of asthmatics
presenting to a tertiary emergency department with acute
asthma exacerbations, significant treatment disparities
existed between pregnant and non-pregnant women. Failure
of the pregnant women to receive adequate treatment for
their exacerbations may have contributed to prolonged or
recurrent symptoms and more frequent healthcare
1440 J.W. McCallister et al.utilization. Poorly controlled asthma in pregnancy increases
the risk of adverse perinatal outcomes and potential harm to
the fetus is more likely to result from severe uncontrolled
asthma than from the medications used to treat it.5 Preg-
nancy should be considered an indication for maximizing
therapy during an exacerbation, rather than withholding it.
All members of the healthcare team should work together to
ensure optimal care of the pregnant asthmatic.
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